# Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

> **NCT03407859** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Therapy Related Leukemia

## Interventions

- **BIOLOGICAL:** Sequential Treatment With different CART

## Key facts

- **NCT ID:** NCT03407859
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03407859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03407859, "Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03407859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*